Cellestia Biotech

Cellestia Biotech, based in Basel, Switzerland, was founded in 2014 as a spin-off from Ecole Polytechnique Fédérale de Lausanne, EPFL. The lead development compound of Cellestia is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor indicated for treatment of patients with NOTCH-dependent leukemia, lymphoma and solid tumors. PPF Group announced an investment in Cellestia Biotech in January 2017 (see the press release here). For more information please visit: http://www.cellestiabiotech.com/.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies